DK2173891T3 - Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III - Google Patents

Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III

Info

Publication number
DK2173891T3
DK2173891T3 DK08775319.0T DK08775319T DK2173891T3 DK 2173891 T3 DK2173891 T3 DK 2173891T3 DK 08775319 T DK08775319 T DK 08775319T DK 2173891 T3 DK2173891 T3 DK 2173891T3
Authority
DK
Denmark
Prior art keywords
cortexolone
propionate
alpha
crystalline form
form iii
Prior art date
Application number
DK08775319.0T
Other languages
English (en)
Inventor
Mauro Ajani
Luigi Moro
Original Assignee
Cosmo Dermatos Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40278805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2173891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo Dermatos Srl filed Critical Cosmo Dermatos Srl
Application granted granted Critical
Publication of DK2173891T3 publication Critical patent/DK2173891T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/005—Degradation of the lateral chains at position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DK08775319.0T 2007-08-03 2008-07-24 Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III DK2173891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001616A ITMI20071616A1 (it) 2007-08-03 2007-08-03 Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
PCT/EP2008/059702 WO2009019138A2 (en) 2007-08-03 2008-07-24 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Publications (1)

Publication Number Publication Date
DK2173891T3 true DK2173891T3 (da) 2014-04-28

Family

ID=40278805

Family Applications (4)

Application Number Title Priority Date Filing Date
DK15175112.0T DK2966175T3 (da) 2007-08-03 2008-07-24 Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK12173152.5T DK2503004T3 (da) 2007-08-03 2008-07-24 Cortexolon-17alfa-propionat i krystallinsk form I
DK12173228.3T DK2503005T3 (da) 2007-08-03 2008-07-24 Cortexolon-17alfa-propionat i krystallinsk hydratform IV
DK08775319.0T DK2173891T3 (da) 2007-08-03 2008-07-24 Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK15175112.0T DK2966175T3 (da) 2007-08-03 2008-07-24 Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK12173152.5T DK2503004T3 (da) 2007-08-03 2008-07-24 Cortexolon-17alfa-propionat i krystallinsk form I
DK12173228.3T DK2503005T3 (da) 2007-08-03 2008-07-24 Cortexolon-17alfa-propionat i krystallinsk hydratform IV

Country Status (25)

Country Link
US (9) US8785427B2 (da)
EP (5) EP3521298A1 (da)
JP (3) JP5646992B2 (da)
KR (1) KR101495192B1 (da)
CN (3) CN101743316B (da)
AR (3) AR072235A1 (da)
AU (1) AU2008285784B2 (da)
BR (1) BRPI0814163A2 (da)
CA (3) CA2871039C (da)
DK (4) DK2966175T3 (da)
ES (4) ES2462946T3 (da)
HR (4) HRP20140421T1 (da)
HU (3) HUE026507T2 (da)
IT (1) ITMI20071616A1 (da)
LT (1) LT2966175T (da)
MX (4) MX363238B (da)
NZ (3) NZ615953A (da)
PL (4) PL2503004T3 (da)
PT (4) PT2966175T (da)
RS (4) RS53310B (da)
RU (2) RU2482190C2 (da)
SI (4) SI2503004T1 (da)
TR (1) TR201909129T4 (da)
WO (1) WO2009019138A2 (da)
ZA (2) ZA201000587B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3006453A1 (en) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
US20240018181A1 (en) 2020-10-19 2024-01-18 Industriale Chimica S.R.L. Process for the production of 21-(acetyloxy)-17-(propionyloxy)-pregn-4-ene-3,20-dione
IT202100008429A1 (it) 2021-04-06 2022-10-06 Farmabios Spa Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata
CN114410727B (zh) * 2022-01-25 2023-09-19 山东诺明康药物研究院有限公司 一种克拉考特酮的制备方法
CN115073546A (zh) * 2022-06-01 2022-09-20 浙江神洲药业有限公司 一种新型雄激素受体抑制剂的制备方法
CN115466301A (zh) * 2022-08-29 2022-12-13 扬州奥锐特药业有限公司 一种甾体化合物，其晶型a及它们的制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB791771A (en) 1954-07-29 1958-03-12 Merck & Co Inc Steroid compounds
US2985650A (en) * 1958-05-28 1961-05-23 Syntex Sa 6alpha-ammonio-derivatives of 11-keto cortical hormones
DE1195748B (de) 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
NL6605514A (da) * 1966-04-25 1967-10-26
NL6605515A (da) * 1966-04-25 1967-10-26
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US3733318A (en) 1972-03-23 1973-05-15 Syntex Corp 21-orthoesters of cortical steroids and methods of preparing same
JPS5910799B2 (ja) * 1975-07-15 1984-03-12 大正製薬株式会社 プレグナン系ステロイド １７−エステル類の製法
GB2109817B (en) 1981-11-18 1985-07-03 Ibm Electrodeposition of chromium
DE3243482A1 (de) 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4920216A (en) 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5264428A (en) * 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH08135789A (ja) 1994-11-09 1996-05-31 Komatsu Ltd 車両の油圧式駆動装置の変速装置およびその変速制御方法
DE19653730C2 (de) 1996-12-11 1999-06-24 Schering Ag Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
AU743399B2 (en) 1997-06-25 2002-01-24 Teijin Limited Vitamin d3 derivatives and remedies for inflammatory respiratory diseases prepared from the same
PT1390377E (pt) 2001-05-22 2006-06-30 Pfizer Prod Inc Nova forma cristalina da azitromicina
ITMI20011762A1 (it) * 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
JPWO2003080042A1 (ja) * 2002-03-27 2005-07-21 塩野義製薬株式会社 軟骨細胞外基質分解阻害剤
WO2004014935A1 (de) 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
AU2003278744B2 (en) 2002-08-28 2010-07-29 Harbor Biosciences, Inc. Therapeutic treatment methods
DE602004021238D1 (de) 2003-03-05 2009-07-09 Merck Frosst Company Stickstoffmonoxid freisetzende prodrugs von diaryl-2-(5h)-furanonen als inhibitoren von cyclooxygenase-2
US20050008704A1 (en) 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ITMI20051695A1 (it) * 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
ITMI20132157A1 (it) 2013-12-20 2015-06-21 Cosmo Dermatos Srl Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Also Published As

Publication number Publication date
MX363238B (es) 2019-03-15
EP3521298A1 (en) 2019-08-07
EP2503005A2 (en) 2012-09-26
PT2503004E (pt) 2015-12-09
MX2019003639A (es) 2019-06-17
EP2966175B1 (en) 2019-05-08
SI2173891T1 (sl) 2014-06-30
RS54361B1 (en) 2016-04-28
HUE026206T2 (hu) 2016-05-30
EP2503004A1 (en) 2012-09-26
EP2503004B1 (en) 2015-09-02
US20140179654A1 (en) 2014-06-26
CN104861023A (zh) 2015-08-26
SI2966175T1 (sl) 2019-08-30
US20220280531A1 (en) 2022-09-08
PL2503005T3 (pl) 2016-05-31
JP2010535173A (ja) 2010-11-18
US20160051566A1 (en) 2016-02-25
AU2008285784A1 (en) 2009-02-12
NZ600767A (en) 2013-11-29
CA2871025A1 (en) 2009-02-12
AR111351A2 (es) 2019-07-03
JP6174645B2 (ja) 2017-08-02
EP2173891B1 (en) 2014-02-12
US20190083511A1 (en) 2019-03-21
HUE044237T2 (hu) 2019-10-28
EP2966175A1 (en) 2016-01-13
ITMI20071616A1 (it) 2009-02-04
EP2503005A3 (en) 2012-10-03
AR111202A2 (es) 2019-06-12
MX363701B (es) 2019-03-29
WO2009019138A3 (en) 2009-10-15
RU2010107599A (ru) 2011-09-10
ES2462946T3 (es) 2014-05-26
PL2966175T3 (pl) 2019-11-29
RS53310B (en) 2014-10-31
HRP20151174T1 (hr) 2015-12-04
SI2503005T1 (sl) 2015-12-31
JP5646992B2 (ja) 2014-12-24
JP6108944B2 (ja) 2017-04-05
US20200155572A1 (en) 2020-05-21
BRPI0814163A2 (pt) 2015-01-20
DK2966175T3 (da) 2019-07-01
PT2173891E (pt) 2014-05-19
AU2008285784B2 (en) 2014-06-26
CN104861023B (zh) 2017-04-12
KR101495192B1 (ko) 2015-02-25
AR072235A1 (es) 2010-08-18
ES2551910T3 (es) 2015-11-24
SI2503004T1 (sl) 2015-12-31
CN101743316A (zh) 2010-06-16
LT2966175T (lt) 2019-08-26
RS54354B1 (en) 2016-04-28
DK2503005T3 (da) 2015-11-16
US10159682B2 (en) 2018-12-25
PL2503004T3 (pl) 2016-05-31
CA2871039A1 (en) 2009-02-12
CN103450304A (zh) 2013-12-18
CN101743316B (zh) 2013-09-04
PT2503005E (pt) 2015-12-09
US20160326210A1 (en) 2016-11-10
ZA201000587B (en) 2011-04-28
ZA201100133B (en) 2014-03-26
JP2013163683A (ja) 2013-08-22
CA2691445A1 (en) 2009-02-12
NZ615953A (en) 2015-03-27
CA2871039C (en) 2017-11-28
EP2503005B1 (en) 2015-09-02
TR201909129T4 (tr) 2019-07-22
PL2173891T3 (pl) 2014-07-31
US8785427B2 (en) 2014-07-22
NZ599437A (en) 2013-11-29
EP2173891A2 (en) 2010-04-14
HRP20151298T1 (hr) 2016-01-01
PT2966175T (pt) 2019-06-27
US9433628B2 (en) 2016-09-06
RU2012113839A (ru) 2013-10-20
KR20100044845A (ko) 2010-04-30
HRP20191143T1 (hr) 2019-09-20
RU2599452C2 (ru) 2016-10-10
US9486458B2 (en) 2016-11-08
US11938141B2 (en) 2024-03-26
US20110092472A1 (en) 2011-04-21
US10716796B2 (en) 2020-07-21
ES2732326T3 (es) 2019-11-21
CA2691445C (en) 2017-11-28
US10166245B2 (en) 2019-01-01
HRP20140421T1 (hr) 2014-06-06
US20230104965A1 (en) 2023-04-06
US11207332B2 (en) 2021-12-28
RS58950B1 (sr) 2019-08-30
HUE026507T2 (hu) 2016-06-28
US20160324873A1 (en) 2016-11-10
DK2503004T3 (da) 2015-11-02
CN103450304B (zh) 2016-05-25
WO2009019138A2 (en) 2009-02-12
JP2016014045A (ja) 2016-01-28
MX2010001256A (es) 2010-05-17
ES2554934T3 (es) 2015-12-28
RU2482190C2 (ru) 2013-05-20
CA2871025C (en) 2016-05-24

Similar Documents

Publication Publication Date Title
DK2173891T3 (da) Enzymatisk fremgangsmåde for at opnå cortexolon-17-alfa-propionat i krystallinsk form III
HUS2100048I1 (hu) Adenin-származék mint PI3K inhibitor
EP3156494B8 (en) Genome editing in rats using zinc-finger nucleases
IL210855A (en) Annals of Adenine
EP2351847A4 (en) PROCESS FOR THE PRODUCTION OF SOPHOROSELIPIDES
IL207283A0 (en) Dynamic formulas for spreadheet cells
EP2335494A4 (en) PROCESS FOR LIPID CONCENTRATION
BRPI0916499A2 (pt) método de produção de biomassa
FI20080665A0 (fi) Luonnollisen tyyppiset sakkaridikoostumukset
IL211100A0 (en) Process for making 5-azacytosine nucleosides and their derivatives
EP2201088A4 (en) hydroisomerization
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
PT2003949E (pt) Processo e dispositivo para a aceleração do crescimento
BRPI0818249A2 (pt) Método de produção de nucleosídeos
DK2307020T3 (da) Administrationsskema til nitrocatecholer
BRPI0911443A2 (pt) derivados de aminopiridina
DK3117713T3 (da) Fremgangsmåde til fremstilling af mælk i fast form
IL207557A0 (en) Process for the preparation of pregnane derivatives
AU2007259425A8 (en) Benzimidazole derivatives which are to be used as anatgonist for the CB1-receptor
FI20116245A (fi) Konstellaatiomuokkaus OFDM:ää varten
EP2321330B8 (de) Verfahren zur herstellung phosphatverbrückter nucleosid-konjugate
IT1390857B1 (it) Gruppo falciatrice frontale perfezionato per trattori
NO20081658L (no) Festeanordning for stol
DK2280691T3 (da) Krystallinsk DOPC
GB0812895D0 (en) Crystalline carbohydrate derivative